Good day, and thank you for standing by. Welcome to the Profound Medical Third Quarter 2025 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising that your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Stephen Kilmer, Investor Relations. Please go ahead. Thank you. Good afternoon, everyone. Let me start by pointing out that this conference call will include forward-looking statements within the meaning of applicable securities laws in the United States and Canada. All forward-looking statements are based on Profound's current beliefs, assumptions, and expectations, and relate to, among other things, any expressed or implied statements regarding future financial performance and position, and expectations regarding the efficacy of Profound's technologies in the treatment of prostate cancer, benign prostatic hyperplasia or BPH, uterine fibroids, adenomyosis, pain palpitation of bone metastases, desmoid tumors, osteoid osteoma, and the potential treatment of abdominal cancers and hypothermia for cancer therapy. Such statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from those implied by such statements. No forward-looking statement can be guaranteed. Listeners are cautioned not to place any undue reliance on these forward-looking statements, which speak only as of the date of this conference call. Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law. Representing the company today are Dr. Arun Menawat, Profound's Chief Executive Officer, Rashed Dewan, the company's Chief Financial Officer, Dr. Mathieu Burtnyk, Profound's President, and Tom Tamberrino, our Chief Commercial Officer. With that said, I'll now turn the call over to Rashed. Good afternoon, everyone, and welcome to our Third Quarter 2025 Conference Call. On behalf of the management team and everyone at Profound, I would like to thank you for your ongoing interest in our company. For those of you who are shareholders, we appreciate your continued interest and support. I will turn the call over to Mathieu in a moment to provide commercial updates. However, before I do, I would like to provide a brief summary of our Third Quarter 2025 financial results. To streamline things, all of the numbers I will refer to have been rounded, so they are approximate. For the three-month period ending September 30, 2025, the company recorded revenue of $5.3 million, with $4.1 million from recurring revenue and $1.2 million from one-time sale of capital equipment. Third Quarter 2025 revenue was up 87% from $2.8 million for the same three-month period a year ago. Gross margin in Q3 2025 was 74.3% compared to 63.1% in Q3 2024. Total operating expenses in the 2025 Third Quarter, which consist of R&D and SG&E expenses, were $12.8 million compared with $10.8 million in the Third Quarter of 2024. Overall, the company recorded the Third Quarter 2025 net loss of $8 million or $0.26 per common share, down from a net loss of $9.4 million or $0.38 per common share for the same three-month period in 2024. As of September 30, 2025, Profound had cash of $24.8 million. As Arun will discuss later in the call, we believe that we are now on a path to profitable growth. In keeping with that, we expect our cash fund to decline and eventually turn cash flow positive as our revenue continues to grow and our margins remain high. That said, we have recently received some inquiries about potential future financing plans and if we have a shelf registration statement filed in the U.S. With respect to our thoughts on future financing, while we have not made any current plans, we'd like to assure investors that we will continue to be opportunistic with the goal of limiting shareholder dilution as much as is practicable. With respect to a shelf, we do not currently have one in place but plan to file an S3 later this evening as a matter of good corporate housekeeping to keep our options open as we move forward with our financial growth. With that, I will now turn the call over to Mathieu for an update on clinical and development activities. Thank you, Rashed, and good afternoon. Last quarter, we initiated the pilot release of our new TULSA AI Volume Reduction Software, which is specifically designed to shrink benign enlarged prostates primarily caused by the condition known as BPH. I am delighted to announce today that the full product release will be launched at this year's annual meeting of the Radiological Society of North America, or RSNA, which is taking place in Chicago at the end of this month. The new volume reduction software leverages AI-powered planning and accelerated ablation together with the same TULSA hardware, the same regulatory indication for use, and the same reimbursement codes to provide fast and efficient workflows which are on par with mainstream BPH treatment options. The pilot release had two primary objectives. The first was to demonstrate total procedure time of 60-90 minutes, and the second was to obtain early user feedback to incorporate into the complete feature set included in the full product release. Both of these objectives have been resolutely met. To date, early surgeon feedback has exceeded our expectations. With the precision of real-time MRI guidance and the flexibility of transurethral ultrasound ablation, surgeons have described that they can create treatment designs that mimic any other BPH procedure, whether it's coring the apple like Rezūm and Aquablation, or a more complete resection like HoLEP. In other words, no matter the prostate shape or size and the needs of the patient for a small or large ablation, TULSA with volume reduction can do it. TULSA also goes beyond with the ability to precisely carve out the ejaculatory ducts, visualize and target cancer lesions, or even prophylactically ablate regions suspicious for cancer, such as PI-RADS 3 lesions or in patients with high PSA or that have a known genetic risk. Surgeons have also described how they can use the efficiency benefits of the new software features for patients with prostate cancer. With the improved workflows and flexibility to customize each treatment to the individual patient, surgeons will have the ability to create what they call TULSA days, where they stack multiple cases in one day with predictable and efficient outcomes, whether with prostate cancer, BPH, or patients with both cancer and BPH. That is all with no overnight stay, no blood loss, no fulguration, no grade 4 adverse events, and no need for patients to discontinue their anticoagulant therapy. The pilot launch of the volume reduction software has motivated incremental increase in BPH procedures from Q2 to Q3 and into the first half of Q4. With the full product launch at RSNA later in November, we believe we are well positioned to demonstrate increased utilization in BPH with double-digit% of our total procedures in 2026. Speaking of RSNA, we're just two short weeks away from the meeting in Chicago, where the TULSA-PRO will be featured prominently. Our booth will feature the full product launch of our new TULSA AI Volume Reduction Software, and the final perioperative outcomes from the Kapton trial will be presented by Dr. Peji Ghanouni from Stanford. In addition, the Innovation Theater will host a special session titled "Discover TULSA-PRO: AI-Powered MRI-Guided Precision Prostate Ablation," which will be presented by both Dr. Joseph Bush from the Bush Center as well as Dr. Daniel Costa from the MD Anderson Cancer Center. In a separate session, Dr. Bush will deliver an oral presentation describing his TULSA outcomes from a cohort of 160 patients. Finally, the TULSA procedure will be the subject of three different educational exhibits from each the University of Texas Southwestern, the NIH, or the National Institute of Health, as well as from the Sapporo Hokuyu Hospital in Japan. We certainly look forward to an impactful event. I would like to take a moment to provide an update on our Kapton trial. During our last earnings call, we announced that the Kapton trial was fully recruited and all patient treatments were complete, making it the first randomized controlled trial ever comparing a new technology to the standard of care of robotic radical prostatectomy to successfully recruit to target. We believe one of the reasons for the success is the capability of TULSA to perform safe and effective whole gland ablations, making it a true incision-free prostatectomy as opposed to other ablative procedures that can only target small unifocal disease. Completion of all patient treatment marks a significant milestone as it cements the timing of data readout, including the primary one-year safety and three-year efficacy outcomes. The trial, however, is already collecting important secondary endpoints. The final perioperative outcomes will be presented at RSNA as well as at the Society of Urological Oncology, or SUO, in early December. The data will prove TULSA's superiority to robotic surgery in blood loss, hospital stay, post-op pain, and time of recovery. This will be followed closely by its peer-reviewed publication, which we expect to be submitted to a scientific journal before the end of this year, which we believe will be the beginnings of a key driver towards gaining favorable recommendation from the relevant professional society treatment guidelines and positive reimbursement coverage from private payers. Since RSNA starts in just a few days and Kapton side effect data would have been needed to have been submitted prior to any presentation, it won't be part of what's presented there this year. However, we are considering appropriate ways to unveil it relatively soon without risking breaking any embargoes ahead of AUA in May. Please stay tuned on that front. With that, I'll turn the call over to Tom. Thank you, Mathieu. In Q3 2025, we continue to build on the commercial momentum we established earlier this year. We saw strong traction with our TULSA-PRO platform. As Rashed mentioned earlier, we achieved a year-over-year revenue increase of 87%, up from $2.8 million in Q3 2024. Our gross margin also improved significantly, reaching 74% compared to 64% last year. This reflects the growing efficiency and scale of our commercial operations. As of now, we have 70 TULSA-PRO sites, and the company's TULSA-PRO qualified sales pipeline is also growing and currently stands at 93 new systems being classified within one of the verify, negotiate, and contracting stages, which are the final three phases of our sales process. Q3 was a true commercial inflection point. We're seeing broader adoption of TULSA-PRO across both academic and community hospitals. That's largely due to increased awareness of the system's clinical benefits and the streamlined reimbursement pathway made possible by the category one CPT code. Our team remains focused on targeting high-volume urology centers and supporting physician training. We're leveraging positive clinical outcomes and patient testimonials to drive engagement and deepen relationships with our customers. Looking ahead, I'm confident in our ability to sustain this growth. We are well positioned to capitalize on the expanding interest in image-guided interventions, and we're continuing to scale our commercial footprint while validating our technology in the prostate care market. We have established flexible business models to drive adoption. With our 25 for 200 program, hospitals performed 25 cases in year one for roughly $200,000 with a path to capital conversion. This model allows hospitals to break even on a per procedure basis, typically by the 12th case, while providing Profound with committed revenue. Our standing pricing model includes a capital system priced around $500,000 and disposables averaging $5,500 per procedure. We're seeing success at our model sites. In Texas, the prime hospital system is demonstrating Medicare profitability. In the near future, we are confident that our TULSA+ sites will prove that integration with IMRI can deliver a payback in under two years. Rather than competing with HIFU, IRE, or cryophysicians, we're collaborating with them. These clinicians already prefer alternatives to radical prostatectomy or radiation, but their current options limit patient volume. TULSA's versatility enhances their offerings, and over time, many of them gravitate toward adopting our technology. We're also building strategic partnerships on a global basis, whether that be through distribution agreements with the likes of Al Faisaliah Medical Systems in Saudi Arabia, Getz Healthcare in Australia and New Zealand, or partnerships with OEMs such as Siemens. There's more to come on the partnership front, and I'm excited about the opportunities ahead. Thank you for your time. I will now turn the call over to Arun. Thank you, Tom, and good afternoon, everyone. As you just heard from Tom, after experimentation and refinement, both his team and their messaging to potential customers, we now know how to sell TULSA programs. As I have presented earlier this week at the Stifel Conference, we believe we are now on a path to not just grow, but profitably grow. The math to achieve this target is simple. With just 200 TULSA programs using existing MR install base, assuming 15 TULSA procedures per site per year and $5,500 in recurring revenue to Profound per procedure, we would be at $55 million in procedure revenue, about $10 million in annual service revenue, and selling 40 TULSA-PRO systems per year at $500,000, $20 million in new capital revenue. That will put us around $85 million annual revenue. With 70% gross margin already achieved, we would be profitable well before that. Putting this together with what Mathieu had already discussed, the trifecta is finally here. The MR is here, and high MRI is coming rapidly. In the very near term, our strategy is to focus on existing MRs and achieve an install base of 200 TULSA-PRO sites. That is where our sales team is focused right now. Simultaneously, we are in the final stages of achieving compatibility with the new Siemens interventional MR, the FREEmax. We believe that as early as next year, TULSA+ sites with the FREEmax plus TULSA-PRO will be operational, opening the door to the future, the interventional MR suite with TULSA. These sites will further streamline the patient and staffing workflow, making it easier to further drive adoption. Second, we are now beginning to get confirmation from multiple hospitals that they are being paid for all qualified Medicare patients and that they are satisfied with the amount received. In addition, many commercial payers are also now covering the procedure on a case-by-case basis. In some cases, that's based on pre-approvals. In some cases, they are being submitted after the procedure and being paid. In others, there are initial denials, but we are getting reversals through appeal. While that is still a bit of a mixed bag at this stage, as we have said earlier, we're tracking appropriately at this stage and remain confident that we will begin to secure national or regional coverage decisions from the commercial payers starting middle of next year, as there is ample clinical data to support our applications. Third, we are excited to be upgrading our AI-powered software to include simpler patient workflow for patients who suffer from BPH symptoms. Having the flexibility to treat a variety of patients with prostate cancer and now with BPH gives our sites the flexibility to create a treatment day, which leads to efficiency and easier scheduling for the hospital staff. We believe that altogether, this trifecta gives us a good chance to not only grow in high double digits, but with high margins, we believe we can achieve profitability and continue to grow profitably. Before my closing remarks, I would like to take a few moments to talk about our second large opportunity, Sonalleve. We're getting more and more incoming calls from both TULSA users and non-TULSA sites that are interested in interventional MRI and the ability to also treat diseases in the body cavity, such as diseases of the uterine adenomyosis and fibroids, and cancers such as liver and pancreatic cancers. In fact, Al Faisaliah Medical Systems, who we announced an exclusive distribution agreement with for Saudi Arabia earlier this week, originally called us about Sonalleve. Once they were introduced to TULSA-PRO as well, they quickly wanted to discuss both, and not only for Saudi Arabia, but also potentially other countries they're active in, such as other Gulf region countries and Brazil, where they own multiple hospitals. Sonalleve, which is offered primarily as a one-time capital sale, uses the same MR imaging and tomography technology as TULSA-PRO and combines that with focused ultrasound from outside the body to treat disease. There are currently 10 Sonalleve devices operational in parts of Europe, China, and Southeast Asia, where over 4,000 women have already been treated with the technology for adenomyosis and uterine fibroids, diseases of the uterus that can cause chronic pain and heavy and/or prolonged menstruations. Treatment with Sonalleve has demonstrated pain and symptom relief without affecting the ovarian reserve and with reports of women preserving their fertility. Sonalleve is also now being used in research and clinical trials in Europe for the ablation of pancreatic cancer tissue and other oncological diseases. To summarize, Profound is the only company that combines the real-time imaging and tomography capabilities of MR and AI-driven treatment designs to allow physicians to precisely and gently address diseased tissue without any incision, associated tissue boiling or charring, blood loss, severe or prolonged pain, or need for overnight hospital stay. The sales team is clearly delivering, and the pipeline, as we define it now, is over 50 as compared to 80 in mid-August. TULSA-PRO install base now sits at 70, and we expect to reach at least 75 installs by the end of the year. The new TULSA AI Volume Reduction Module to treat patients with BPH symptoms is significantly reducing the procedure time, making it very competitive with other BPH treatment technologies. This application has the potential to add 400,000 patients to our annual TAM, essentially tripling our previous TAM. Adding the BPH module also enables physicians to create a full TULSA day, during which both their prostate cancer patients and BPH patients are treated. From the perspective of ease of scheduling and creating a TULSA program, this ability is important. The second technology platform, Sonalleve, is poised to start becoming a more core part of our story in the coming months and quarters, both internationally and in the United States. Finally, as user interest in Profound Technologies continues to build, we're deploying our own direct sales team in North America while partnering with select strategic distribution partners to support the business potential and the customer base in other parts of the world for both TULSA-PRO and Sonalleve. This ends our prepared remarks for today. With that, we're happy to take any questions you might have. Operator. Certainly. As a reminder to ask a question, please press star 11 on your telephone and wait for your name to be announced. To withdraw your question, please press star 11 again. Please stand by while we compile our Q&A roster. Our first question comes from Ben Haynor of Lake Street Capital Markets. Ben, your line is open. Good afternoon, gentlemen. Thanks for taking the questions. First off, for me, it's just very encouraging to see the utilization jump up in Q3 after kind of a frustrating first half of the year. It does sound, based upon your commentary in the press release, that that trend continues into Q4 thus far. Could you provide a little bit more color and maybe characterize how that's tracking? Yeah. I'm going to let Tom answer that because he's a fantastic pipeline. Tom, if you could please go ahead. Yeah. Happy to, Ben. Thank you for being here with us, and thank you for the question. To make sure I'm hearing correctly, specifically, you're calling out the improvement in utilization, right, treatments that have been completed here in Q3, and whether we have experienced that trend continuing to date through the beginning part of Q4. Is that correct? Yeah. Basically, are you seeing that acceleration continue as we close out the year? The answer is yes. What I can tell you is that the tailwinds that are coming online are the fact that the CPT-1 coding that we have referred to and the reimbursement associated with that through Medicare is coming through exactly as we thought it would. There is tremendous validity in terms of the ability to provide treatment to men who are Medicare eligible, added to which Indignity, our market access and patient access team, are doing a tremendous job of working with individual patients on obtaining private insurance coverage on a one-to-one basis in the absence of any payer policies, right? We do not have any negative payer policies nor positive payer policies at this time. We have a corporate strategy to address that with the private payers as well. What's happening is we've got the tailwind of Medicare patients coming online, right, moving away from a cash pay-only market. We've got individual wins with private insurance companies. Added to that, we've got a growing body of evidence, as has been stated through not only the Bush press release that came out, but also several others, that there's an appetite for this technology across the globe. I'm not sure if you've met urologists, but they're a competitive bunch. One country wants to get started before another country. That also comes back to the U.S. as well, where if you've trained with another physician during your days in fellowship or residency, and they're using it in a country that is not this country, there's competitive juices flowing. There are multiple factors that are going into driving that adoption. Let's not forget the most important reason why is that patients are seeking TULSA-PRO out based on their own research and edification of the results of other men who have faced prostate disease. That is our greatest referral base. Excellent. That is very helpful. And then on the folks that have gotten commercial payers to pay, and typically you see commercial rates roughly double Medicare rates, is that about what you have seen? Do you have sufficient experience there to make any comments? Yes. Ben, Mathieu, I know you have some numbers too, but we are starting to get a number of sites that are willing to share the numbers. The Medicare numbers are definitely where they are supposed to be, but the numbers from private payers are significantly higher. Mathieu, if you have some numbers, please go ahead and talk about that. Yeah, absolutely. To Arun's point, we are starting to get some information from some of our sites as we're working with them on ensuring all of their charges are set up properly and so on. The volume of Medicare patients is higher than the commercial ones that are getting approved. Even from a Medicare perspective, there's a site that's kind of, call it national average. They have confirmed that they are receiving about $13,000 for Medicare as well as Medicare Advantage patients, which is right along the CMS rule. For commercial payers, I was actually surprised to see it. I mean, this is at one particular site. I don't know if it's necessarily applicable to all sites around the country, but they're seeing payments like payment dollars from $25,000 all the way up to $65,000 per patient. When you look at sort of the contribution margin from those, again, even on the Medicare and Medicare Advantage, they're actually making sort of $3,000-$4,000 per patient in a contribution margin perspective. Of course, those that are the payers that are paying in that $25,000-$65,000 range, it's much more significant there. Seeing very, very positive numbers from those sites that are willing to share that information with us. That's an initiative that we're going to continue to go through in Q4 of this year as well as into 2026. Cool. That's great. Lastly for me, and then I'll jump back in to you again, 93 folks or 93 sites that are in the engage stage. How many of those do you expect to kind of fall out and ultimately become customers? Any over what time period sort of information that you could share there would be fantastic. Thank you. Ben, I know you would do the same for me if I maybe misstated. I want to make sure we clarify. These are in the verify, negotiate, and contracting phases, which is the tail end of our pipeline that then leads into closing, right? The engage portion is further up the pipeline. This is a much different subset of accounts that we're referring to. Yeah. Okay. So this one is closing. How do you expect those to kind of fall out? Yeah. I mean, I think, Ben, the way to think about this, this is a real pipeline, which is why, as Tom described, we are making it available because I realize everyone is wondering how real the future looks like. And it is kind of a highly vetted pipeline. I think that two things. One is that it does give us good confidence for the Q4 growth. I think for 2026, I do not think they are all going to close in one quarter, obviously. I think the way to think about this is 2025, Q4, the pipeline, a good bit of it will close. Then 2026, we are starting with a really good pipeline to be able to continue to grow. Excellent. Thanks, guys. Thank you very much. Thank you, Ben. Our next question is coming from John McAuley of Stifel. Your line is open, John. Hi, Arun and team. Thanks for taking the question. I wanted to start off today just on setting expectations for the fourth quarter. Again, apologies if I missed it, but in the past, you've talked about 70-75% growth for the year. And now with the strong three-quarter report, there's a smaller implied step up to get to that range. Just wanted to hear your general thoughts as we head into the fourth quarter and expectations in terms of the revenue and whether that 70-75% guidance still stands. Yes, John, that's a great question. I think that based on the information we're provided, Tom and the team have already closed three sites, which is why our install base is now at 70. Hopefully, that gives you some confidence. The pipeline information hopefully gives you confidence as well. Where we are, we remain comfortable with that 70% growth target. We have delivered the first quarter with growth. We think we can deliver the second quarter with growth and then continue to grow. I think bottom line, John, we're comfortable with that 70% growth target. Got it. That's helpful. As a follow-up, gross margins stepped up again, now a little over 74% here. Can you just talk about the capital versus consumable dynamic? What's driving the acceleration and what's a reasonable long-term target here? I think we are more likely than not probably at the right place on gross margin. The reality is that the margin is about the same on both the recurring revenue as well as the capital. And so, John, I would say using a number between 70-75%, we always thought we would get above 70. We are kind of feeling like this is about where we would like to be running the business in the low 70% range. Thanks, Arun. Just if I could sneak in one more to follow up on Ben's question at the beginning. In the three stages of the negotiation or in the contracting that you're talking about, these three latter stages, just want to put a finer point on. I mean, what's the fallout rate here from stage to stage? For the one that's in the final range, what sort of% closing rate are you seeing? For before that, what's the% chance that it reaches that final stage of the pipeline and so on and so forth? Is that what I'm getting at? Yeah. Yeah, Yeah, I do. I understand that very well. I would say, given that the pipeline is new and so on, our ability to really predict the specific result is not as high because we have less data. From our history, from our prior company and so on, I would say for the next couple of quarters, we think that sort of pipeline in the 50%+ range will ultimately close. We think as our sales team gains more experience, that number will more than likely increase to 65%. This is where we do not put things into that tail end until we have at least a 50% confidence that they will close. Excellent. That's really helpful. Thanks for taking the questions. Yeah. Absolutely. As a reminder to ask a question, please press star 11 on your telephone and wait for your name to be announced. Our next question will be coming from Michael Freeman of Raymond James. Your line is open. Good evening, gentlemen. Congratulations on these big results. Just a detail, I'm curious, you mentioned 70 total units installed. With your pre-announcement, you mentioned 67. Is the 70 units total installed, is that as of today's date, or did this happen in Q3? That's right, Michael. The team really has been working pretty hard. The first three deals of this quarter are already closed. That is why we decided we would share with you what it is as of now, as an end of the quarter. Perfect. Okay. That's helpful. More data the better. Now, Mathieu went over a bunch of upcoming data reveals. I wonder if you could—I wonder if you could just review for us what you think are going to be the highest impact data reveals that will happen over the next few months. What do you think would be dial-moving in terms of things like commercial reimbursement and general uptake? Yeah. It's a very good question because more and more our physicians are pretty convinced that the TULSA technology is clinically efficacious and from side effects significantly better because many of them have done their own publications and research. As Tom and Mathieu have talked about, many of our sites have now done 100, 200-plus cases. Clinical outcomes is people are beginning to get there. I think where it will have the most impact is going to be ultimately in getting to the guidelines and to getting the reimbursement coverage from all insurance companies. I think from that perspective, I know everybody is looking for a VR2, but I think the impact is going to be on the high level. I think it will ultimately impact serious growth for our company. At the moment, it may not necessarily be the most important data that people are looking for. I think the other set of data that I think people are looking for is the one that actually Mathieu talked about on the BPH side when we can start to show that the patients who have BPH can be treated with our technology in an hour or less, or that to be able to see that a number of these patients also had a comorbidity, which might be early-stage cancer, might be some prostatitis or other. That they could treat those patients for those diseases at the same time. I think that is going to really impact the BPH part of our market. That, I would say, is the number one from a clinical perspective, what I think they're looking for. From the reimbursement perspective, I think we're starting to get the data. The more data we get, I think the easier it will be to start driving adoption of the technology. Okay. All right. Thank you very much. I guess last for me, I do notice that there's more discussion of the Sonalleve recently. I wonder if you could describe the motivation for this renewed focus on the Sonalleve. Yeah, Michael, I'm happy to. I think what happened is that from our end, we have limited resources. We have stayed focused on TULSA, and all of our resources have really been spent on TULSA. In the side, we have about 10 sites running. To be honest, we've supported them with very limited resources, if any. They have continued to do, and the results are amazing. The change that took place this summer is when Histosonics got acquired for $2.25 billion, everybody started looking and saying, "How come we're not paying attention to this other technology?" When we started talking with physicians who we were getting incoming calls from, we said, "We have an MR-based." I think if anything, we were getting more excitement about the fact that we are MR-based because we can see the diseases better. When you look at uterine diseases, you can see the adenomyosis, the abnormal tissue, the fibroids, abnormal tissues, so it can be targeted and maintain the fertility. The trials for pancreatic cancer and the other body cavity disease cancers were actually sponsored by research organizations that are now starting to say, "Hey, these results actually look pretty impressive." I think it is a combination of the business side, having a benchmark, and the fact that IMRI is coming, and the fact that these results are now looking pretty impressive. It is a combination of all of this. It is pretty exciting for us, to be honest. You know well, I do not use the word exciting frequently. It is because I think that we are actually the only company that can create an ecosystem in the end. That ecosystem can be treating these high-volume prostate cancer diseases, the BPH, and then go into the body cavity and go after uterine diseases and then solid organ tumors. We think that there is a real opportunity here, and we're going to stay very disciplined as you know how we are. I do think it's time to start exploring the Sonalleve asset more closely. Thank you very much, Arun. I'll pass the line now. Thank you, Michael. I'm showing no further questions. I would now like to turn the call back to Arun for closing remarks. Thank you. We appreciate your time. As I said at the Stifel conference this week, and we have talked about it already today, we do believe that it is happening. The pipeline is amazing. The sales team is out there. We are really looking forward to updating you on the Q4 and year-end results next year. Thank you so much. This concludes today's conference call. Thank you for participating. You may now disconnect.